Imperial College London
Portrait Picture

DrOthmanAlmusaimi

Faculty of Engineering, Department of Chemical Engineering

Honorary Research Fellow
 
 
 
//

Contact

 

+44 (0)20 7594 6227o.al-musaimi CV

 
 
//

Location

 

438Bone BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Al:2020:10.3390/ph13030040,
author = {Al, Shaer D and Al, Musaimi O and Albericio, F and de, la Torre BG},
doi = {10.3390/ph13030040},
journal = {Pharmaceuticals},
pages = {1--15},
title = {2019 FDA TIDES (Peptides and Oligonucleotides) Harvest},
url = {http://dx.doi.org/10.3390/ph13030040},
volume = {13},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - 2019 has been an excellent year in terms of peptides and oligonucleotides (TIDES) approved by the FDA. Despite the drop in the number of total drugs approved by the FDA in 2019 in comparison with 2018 (48 vs. 59), the total number of TIDES authorized increased (seven vs. three). Year after year, TIDES are increasingly present in therapy, as imaging agents, theragnostic and constituent moieties of other complex drugs, such as antibody drug conjugates. This means a consolidation of these kinds of drugs in the pharmaceutical arena, paving the way in the coming years for the approval of others for diverse medical indications. Here the TIDES approved in 2019 are analyzed in terms of chemical structure, medical target, mode of action, and adverse effects.
AU  - Al,Shaer D
AU  - Al,Musaimi O
AU  - Albericio,F
AU  - de,la Torre BG
DO  - 10.3390/ph13030040
EP  - 15
PY  - 2020///
SN  - 1424-8247
SP  - 1
TI  - 2019 FDA TIDES (Peptides and Oligonucleotides) Harvest
T2  - Pharmaceuticals
UR  - http://dx.doi.org/10.3390/ph13030040
UR  - https://www.mdpi.com/1424-8247/13/3/40
UR  - http://hdl.handle.net/10044/1/94486
VL  - 13
ER  -
Download